Castle Biosciences (CSTL) Current Assets (2018 - 2026)

Castle Biosciences has reported Current Assets for 9 years, with the latest figure at $341.1 million in Q2 2026.

• Quarterly Current Assets fell 2.17% year-over-year to $341.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $341.1 million (down 2.17% YoY) and the FY2025 annual result came in at $361.1 million, changed 0.26% from the prior year.
• Current Assets improved to $341.1 million in Q2 2026 per CSTL's latest filing, from $328.9 million in the prior quarter.
• Over five years, Current Assets peaked at $361.1 million in Q4 2025 and troughed at $269.1 million in Q2 2023.
• A 5-year average of $319.8 million and a median of $324.7 million in 2024 frame the typical range for Current Assets.
• The sharpest annual moves came in 2022 and 2024: Current Assets dropped 23.15% in 2022, then increased 23.3% in 2024.
• Over 5 years, Current Assets stood at $292.3 million in 2022, then rose by 1.15% to $295.6 million in 2023, then gained by 21.82% to $360.2 million in 2024, then climbed by 0.26% to $361.1 million in 2025, then decreased by 5.54% to $341.1 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $341.1 million, $328.9 million, and $361.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.